VALN - Valneva stock rises as EMA accepts COVID vaccine filing panel to begin review

Valneva (NASDAQ:VALN) (OTCPK:INRLF) said the European Medicines Agency (EMA) accepted its marketing authorization application (MAA) for COVID-19 vaccine VLA2001. The French company's stock rose ~9% to €10.94 on May 19 on the Euronext Paris where it trades under the ticker VLA. The company said the acceptance meant that MAA was advancing from the rolling review process and starting a formal review process by the EMA’s Committee for Human Medicinal Products (CHMP). Valneva added that if the CHMP accepts the conditional MAA, it expects to receive a positive opinion by the EMA panel in June. Earlier in the week, Valneva said the European Commission (EC) intended to terminate its advance purchase agreement for the inactivated whole-virus COVID-19 vaccine VLA2001. Under the agreement, Valneva had 30 days from May 13, to get a marketing authorization or propose an acceptable remediation plan. The company had said it would work with the EC and member

For further details see:

Valneva stock rises as EMA accepts COVID vaccine filing, panel to begin review